Canadian Cancer Trials Group (CCTG)
Canada's national academic trials group, which ran the CHALLENGE exercise trial and co-led the SABR-COMET oligometastasis trial.
CCTG is based at Queen's University. CHALLENGE (CO.21, NEJM 2025) showed a structured exercise programme improves survival in colon cancer; MA.17 (extended letrozole) and PA.3 (erlotinib in pancreatic cancer) were earlier landmarks.
- CHALLENGE exercise trial
- Breast endocrine therapy trials (MA series)
Dongsheng Tu is the statistician behind decades of CCTG trials, including the erlotinib and cetuximab studies that changed lung and colorectal cancer care.
Runs Canada's academic cancer trials network, which has led practice-changing trials from PA.3 to CO.17 and beyond.
Senior investigator behind CCTG's breast cancer trials, including the MA.17 and MA.32 studies of extended endocrine therapy and metformin.
Pages like this
not linked directly; found by shared links- IdeaPay for supervised exercise the way we pay for drugs
Shares CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer, Exercise & lifestyle oncology, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- IdeaCombine the new anti-wasting antibody with exercise and protein
Shares CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer, Exercise & lifestyle oncology, Colorectal cancer.
- TrialCHALLENGE (CCTG CO.21)
Shares Canadian Cancer Society, Exercise & lifestyle oncology, Colorectal cancer.
- InstitutionPrincess Margaret Cancer Centre
Shares Canadian Cancer Society, Health Canada, Sunnybrook Odette Cancer Centre.
- IdeaPerioperative beta-blocker plus COX-2 inhibitor to reduce metastasis after surgery
Shares No incentive to repurpose cheap drugs, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- IdeaA public fund and label pathway to trial generic drugs against cancer
Shares No incentive to repurpose cheap drugs, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- IdeaCheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress
Shares No incentive to repurpose cheap drugs, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- IdeaPre-consented cohorts that can be randomised to future trials (TwiCs)
Shares Trials enrol too few, too slowly, HR-positive / HER2-negative breast cancer, Colorectal cancer.